Prof. Rebecca Abergel is a co-founder and Chief Scientific Officer of HOPO Therapeutics, Associate Professor of Nuclear Engineering and Chemistry and Associate Dean for Inclusive Excellence in the College of Engineering at the University of California, Berkeley. She is also a Senior Faculty Scientist and the Director of the Glenn T. Seaborg Center at Lawrence Berkeley National Laboratory. Rebecca is an internationally-recognized expert in the biochemistry of the actinides and the treatment and decorporation of internalized radionuclides and heavy metals. In her role as Chief Scientific Officer at HOPO, she leads the company’s scientific strategy and oversees research and development programs aimed at advancing novel metal-binding therapeutics and broad applications of HOPO’s chelation technology.

She is the recipient of an Early Career Award from the U.S. Department of Energy, a Women Chemists Committee Rising Star Award from the American Chemical Society, and is a Fellow of the American Association for the Advancement of Science.

Rebecca received her B.Sc. in Chemistry from the Ecole Normale Supérieure in Paris, France, her Ph.D. in Chemistry from the University of California, Berkeley, and completed a postdoctoral fellowship at the Fred Hutchinson Cancer Research Center in Seattle.

Back